NASDAQ:SESN Sesen Bio (SESN) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free SESN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.63▼$12.9952-Week Range N/AVolume93,330 shsAverage Volume1.07 million shsMarket Capitalization$2.56 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sesen Bio alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Sesen Bio Stock (NASDAQ:SESN)Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit SESN Stock News HeadlinesAugust 4, 2023 | fool.comSesen Bio (NASDAQ: SESN)March 6, 2023 | bizjournals.comAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 2, 2023 | msn.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | finance.yahoo.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsFebruary 28, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 24, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 21, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.February 17, 2023 | stockhouse.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 16, 2023 | businesswire.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | finance.yahoo.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 15, 2023 | finance.yahoo.com5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 14, 2023 | bizjournals.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | msn.comSesen gains 11% on amended terms for merger with CarismaFebruary 14, 2023 | finance.yahoo.comSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerFebruary 6, 2023 | finance.yahoo.comSesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agoFebruary 2, 2023 | finance.yahoo.comSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerFebruary 2, 2023 | finance.yahoo.comThe Petri Dish: Departed White House adviser returns to the BroadJanuary 30, 2023 | finance.yahoo.comSesen Bio Receives NASDAQ Delisting NoticeJanuary 26, 2023 | finance.yahoo.comSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersJanuary 19, 2023 | finance.yahoo.comSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsJanuary 6, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing InvestigationsJanuary 5, 2023 | finance.yahoo.comInvestor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerJanuary 4, 2023 | finance.yahoo.comSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsJanuary 3, 2023 | msn.comSesen Bio investors reiterate plan to vote against Carisma mergerSee More Headlines Receive SESN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SESN CUSIPN/A CIK1485003 Webwww.sesenbio.com Phone(617) 444-8550Fax617-858-0911Employees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax Margin-59.40% Return on Equity6.70% Return on Assets5.41% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.10 Sales & Book Value Annual Sales$40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.39 Book Value$0.78 per share Price / BookN/AMiscellaneous Outstanding Shares203,490,000Free Float196,980,000Market Cap$2.56 billion OptionableOptionable Beta0.83 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesThomas R. CannellPresident, Chief Executive Officer & DirectorMonica ForbesChief Financial Officer & TreasurerStephanie VigueFinance DirectorJeannick CizeauHead of ResearchGlen C. MacDonaldChief Technology OfficerKey CompetitorsCorcept TherapeuticsNASDAQ:CORTMerusNASDAQ:MRUSRocket PharmaceuticalsNASDAQ:RCKTKeros TherapeuticsNASDAQ:KROSPTC TherapeuticsNASDAQ:PTCTView All Competitors SESN Stock Analysis - Frequently Asked Questions How were Sesen Bio's earnings last quarter? Sesen Bio, Inc. (NASDAQ:SESN) issued its earnings results on Sunday, November, 7th. The company reported $7.20 earnings per share for the quarter, beating the consensus estimate of ($1.40) by $8.60. When did Sesen Bio's stock split? Shares of Sesen Bio reverse split on the morning of Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Sesen Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK). This page (NASDAQ:SESN) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sesen Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.